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The complexity of the tumour microenvironment encompasses interactions between cancer and
stromal cells. Moving from 2D cell culture methods into 3D models enables more-accurate investigation
of those interactions. Current 3D cancer models focus on cancer spheroid interaction with stromal cells,
such as fibroblasts. However, over recent years, the cancer immune environment has been shown to have
a major role in tumour progression. This review summarises the state-of-art on immunocompetent 3D
cancer models that, in addition to cancer cells, also incorporate immune cells, including monocytes,
cancer-associated macrophages, dendritic cells, neutrophils and lymphocytes.Introduction
It is clearly established that the progression of malignant tumours
(solid cancers) relies on cell–cell interactions, through inter-
twined communications between cancer cells, cancer stem cells
and stromal cells, and on cell–matrix interactions [1]. The com-
plexity of tumour microenvironments has been recapitulated in
recent years with the use of advanced 3D approaches to cell
culture that provide a means to study such interactions. The
benefits of 3D culture over standard 2D systems and animal
models have been reviewed previously [2]. Since then, 3D models
have improved greatly to mimic specific microenvironmental
cues within a solid tumour. Examples include incorporation of
various extracellular matrix (ECM) proteins or artificial scaffolds
to mimic matrix stiffness and composition, addition of different
types of supporting cells and engineering an angiogenic environ-
ment [3–5].
Complex models are also the ideal platform to study the role
of the immune system in malignancy. The ability of cancer
cells to avoid the immune system is a hallmark of cancer and
immunoediting could even support tumour progression [1].Please cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun
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http://dx.doi.org/10.1016/j.drudis.2016.04.010 Xenografts that incorporate the immune system have been
developed but are expensive, can pose ethical dilemmas and
might not adequately recapitulate the events that occur in
humans. By contrast, 3D cultures could represent an optimal
model to study this element of cancer. Microarray analysis of
mesothelioma spheroids and monolayers showed that forma-
tion of 3D cultures resulted in 112 upregulated and 30 down-
regulated probe sets. The primary function of the upregulated
genes was immune response, wound response, lymphocyte
stimulation and response to cytokine stimulation, whereas
the downregulated genes were responsible for apoptosis [6],
indicating that 3D models can provide improved methods for
studying those responses.
The clinical success of immune checkpoint inhibitors, such as
agents acting on the cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), programmed cell death protein 1 (PD-1) and programmed
cell death ligand 1 (PD-L1) pathways [7], and the growing research
on other immunotherapies create the need to understand the
immune interactions in cancer better and to investigate and design
platforms suited for drug development. This review will cover recent
research efforts in developing complex 3D tumour models that
incorporate immune cells and that can further elucidate the role
of cancer immunoediting and immune interactions. The differentocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
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in Table 1 together with their main characteristics.
Monocytes, macrophages and dendritic cells
Cells from the innate and the adaptive immune responses are
present in malignant tumours (Fig. 1). In this context, cells acquirePlease cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun
TABLE 1
Immune cells and their function in cancer
Cell type Subtype Secretome 
Monocyte [44] Classical (CD14++CD16) IL-8, IL-2, IFN-
IL-12, TNF-a
Non-classical (CD14+CD16+) TNF-a, IL-2,
IFN-g, IL-12
Macrophage [45] TAM with M1
characteristics
TNF-a, IL-1b,
IFN-g, IL-12
TAM with M2
characteristics
VEGF, MMPs,
IL-10
Dendritic cells [46] Myeloid (mDCs,
classical)
IFN-g, TNF-a,
IL-12
Impaired by
cancer cells:
impaired rele
of IFN-g, TNF-
IL-12; enhanc
IL-10 secretio
Plasmacytoid
(pDCs)
IFN-a
Impaired by c
cells: IDO, IL-6
decreased IFN
Myeloid-derived
suppressor
cells (MDSCs) [46]
Monocytic and granulocytic
subpopulations
Arginase I, iN
ROS, IDO
Neutrophils [47] IL-8, CCL2, CC
Increased exp
CD54, CCR5, C
CXCR3, CXCR4
Decreased ex
CD62L, CXCR1
CD16
Innate lymphoid
cells [48]
Natural killer (NK) cells IFN-g 
2 www.drugdiscoverytoday.comdistinctive characteristics that differentiate them from resident
immune cells at other tissues. Monocytes can differentiate into
two functionally distinct subtypes of macrophages: classic, anti-
inflammatory macrophages, known as M1; and M2 macrophages
that promote matrix remodelling, angiogenesis and favour tu-
mour progression [8].ocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
Function
g, Impaired by cancer cells:
decrease in IL-2, IFN-g,
IL-12, TNF-a; increase in
IL-10
Dual tumour effect
Recruited to the tumour
site
Present tumour-associated
antigens and activate
antitumour T cell response
Can promote extravasation
and tumour metastasis
Antitumour effect
Proinflammatory,
antitumour immune
response, production of
cytotoxic factors,
phagocytosis, immune-
editing
Protumour effect
Immunosuppressive, low
antigen-presenting
capability, low cytotoxic
function, high tissue
remodelling activity,
angiogenesis, promoting
metastasis
ase
a,
ed
n
Antitumour effect
Present tumour-specific
antigens
Activate antitumor T cell
response
Protumour effect
Silence immunity and
induce tolerance,
depletion of T cells
ancer
,
-a
Antitumour effect
CD8+ T cell activation
Protumour effect
Suppress CD8+ T cells,
promote differentiation of
TREG
OS, Protumour effect
Immunosuppressive,
induce T cell tolerance,
suppress proliferation of
CD4+ and CD8+ T cells,
induce the development of
TREG
L3, IL-6
ression:
CR7,
pression:
, CXCR2,
Antitumour effect
Increase T cell IFN-g
production and activation,
amplify T cell proliferation
Antitumour cytotoxic
effect
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TABLE 1 (Continued )
Cell type Subtype Secretome Function
Lymphocytes T cells [48–53] gd T cells IFN-g, IL-17, IL-8, TNF and GM-CSF Dual tumour effect
Mostly have a direct
cytotoxic effect but can
have protumour effect
when in a highly
inflammatory milieu
NK T cells IFN-g Antitumour cytotoxic
effect with direct and
indirect cell killing via NK
cells
CD4+ T cells Th1 IL-2, TNF-a and IFN-g Antitumour effect in
conjunction with cytotoxic
CD8+ T cells, promote
macrophage cytotoxic
activity and upregulate
antigen processing and
expression of MHC I and II
molecules in professional
APCs
Th2 IL-4, IL-5, IL-6, IL-10 and IL-13 Protumour effect
Suppression of immune
response to tumour by
inducing T-cell anergy and
loss of T-cell-mediated
cytotoxicity, enhancing
humoral immunity, and
regulating the tumour-
promoting activities of
macrophages
Th17 IL-17A, IL-17F, IL-21, IL-22, IL-26, CCL20 Dual tumour effect
Suppress tumour
progression through
enhanced antitumor
immunity, or promote
tumour progression
through an increase in
inflammatory angiogenesis
Tfh cell CXCL13 Antitumour effect by
recruiting B cells to sites of
inflammation
TREG IL-10, IL-35, TGF-b, galectins Protumour effect by
dampening cytotoxic CD8+
T cell activity
CD8+ T cells Antitumour cytotoxic
effect by binding to
antigen presented by MHC
class I. The major
anticancer effector cells
Memory effector T cell Antitumour effect: can be
reprogrammed into
cytotoxic CD8+ T cells
B cells [54] Regulatory B cells IL-10, TNF-a, TGF-b, IL-21, IL-33, IL-35 Dual tumour effect
Antitumour responses can
be enhanced or
suppressed depending on
the regulatory B cell
subsets recruited to the
tumour site
Plasma cell Antitumour cytotoxic
activity via tumour-specific
complexes
Abbreviations: APC, antigen presenting cell; CCL, CC chemokine or b-chemokine ligand; CD, cluster of differentiation; CXCL, CXC chemokine or a-chemokine ligand; CXCR, CXC chemokine
or a-chemokine receptor; DC, dendritic cell; GM-CSF, granulocyte macrophage colony-stimulating factor; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IL, interleukin; iNOS, inducible
nitric oxide synthase; MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; NK, natural killer; ROS, reactive oxygen species; TAM,
tumour-associated macrophages; Tfh, tumour-infiltrated follicular helper cell; TGF, transforming growth factor; Th, helper T cell; TNF, tumour necrosis factor; TREG, regulatory T cell; VEGF,
vascular endothelial growth factor.
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FIGURE 1
Tumour microenvironment is populated by cells of the innate and adaptive
immune system that can enhance tumourigenesis and tumour progression.
Cancer-associated fibroblasts in the tumour stroma, together with cancer
cells, attract myeloid cells, such as monocytes, which differentiate into
cancer-associated macrophages and dendritic cells, as well as neutrophils;
and lymphoid cells, including lymphocytes and natural killer cells.
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and are associated with poor prognosis [10] and drug resistance
[11]. Spheroid culture [using the hanging drop technique, on low-
attachment plates, or on artificial (agar) or ECM proteins (such as
collagen, basement membrane extract)] has been used to study the
effects of monocytes and macrophages on cancer cells and the
microenvironment (Fig. 2).
An early study using cancer spheroids of a human rectal cancer
cell line (HRT-18) formed on agarose-coated wells (Fig. 2d) showed
that macrophages adhere to the surface of spheroids within
24 hours, can infiltrate them and can cause a disintegration of
cancer spheroids without associated cytotoxicity after 5 days of co-
culture. Additionally, cancer spheroids transferred to a collagen
type I layer showed enhanced migration in the presence of anti-
inflammatory macrophages when compared with proinflamma-
tory or resident macrophages [12]. The early results mimic the in
vivo phenotype of resident cancer-associated macrophages and
their ability to promote tumour progression. Agarose-coated wells
were also used to investigate monocyte recruitment from blood
into fibroblast spheroids. In this scenario, only tumour-associated
fibroblast spheroids were infiltrated by monocytes, whereas nor-
mal fibroblast spheroids were poorly invaded [13]. Additionally,
monocyte migration kinetics were faster for tumour-associated
fibroblast spheroids than for breast cancer spheroids [14], raisingPlease cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun
4 www.drugdiscoverytoday.comthe question of whether immune cells are attracted by cancer cells
or stromal cells. Nevertheless, in a study of squamous cell carci-
noma of the head and neck (SCCHN) there was no difference in
peripheral blood mononuclear cell (PBMC) infiltration between
SCCHN spheroids and SCCHN-fibroblast spheroids. Increasing
PBMC number increased their concentration on the outer surface
of spheroids, but not infiltration. Infiltration of SCCHN spheroids
was, however, enhanced after blocking epithelial growth factor
receptor (EGFR) expression [15]. Further studies on breast cancer
spheroids have helped elucidate the mechanisms behind macro-
phage infiltration. Macrophages have been shown to invade breast
cancer spheroids [SUM159PT cells, oestrogen receptor (ER) nega-
tive, and progesterone receptor (PR) negative anaplastic breast
carcinoma] up to the necrotic core using mechanisms that rely
on the heterogeneity and viscoelasticity of the tumour matrix, as
well as on the action of matrix metalloproteinases (MMPs). Also,
the breast cancer spheroids were able to invade fibrillary collagen
type I, but lost their invasiveness in Matrigel1 (mouse ECM
extract). Addition of macrophages (within the spheroids or added
to Matrigel1) allowed the breast spheroids to invade the matrix,
but this did not enhance cancer invasiveness in collagen [16].
These results indicate that matrix composition also affects the
crosstalk between macrophages and cancer cells. Infiltration of
monocytes and macrophages into breast cancer spheroids (T47D
cells, breast ductal carcinoma) has been shown to be dependent on
RNA-binding protein tristetraprolin (TTP), which regulates im-
mune responses. TTP is downregulated in tumourogenesis and
metastasis. In this 3D model TTP knockdown increased the rate of
monocyte infiltration, with cells mainly distributed in the outer
spheroids areas. Concurrent studies in an in vivo mouse model
showed complementary data [17], suggesting that a 3D spheroid
culture can be successfully used to study cancer immune
responses.
Cancer cell characteristics also appear to influence monocyte
infiltration into breast cancer spheroids. Using different breast
cancer cell lines, the highest infiltration was observed with Hs578T
spheroids (ER-negative carcinoma), intermediate with T47D
spheroids and poor with BT549 (ductal carcinoma), MCF7 (ER-
positive adenocarcinoma) and BT474 (ductal carcinoma) spher-
oids [14], indicating that 3D cultures can replicate cancer with
different molecular characteristics or at different points of the
natural history of the disease. The crosstalk between monocytes
and cancer cells appears to contribute to bad prognosis in inflam-
matory cancers by increasing proteases involved in cell migration,
such as urokinase plasminogen activator (uPA) and MMPs [18]. In
a spheroid model, the crosstalk was shown to be dependent on the
aggressiveness of the cell line. Two different breast cancer cell line
(MCF-7 and MDA-MB-231) spheroids were cultured on top of a
solidified layer of Matrigel1, alone and co-cultured with mono-
cytes. On one hand, the presence of monocytes reduced the
expression of tumour malignancy markers [MMP9, uPA, cycloox-
ygenase (COX)-2, osteopontin (OPN)] in less aggressive breast
cancer spheroids (MCF-7), suggesting a tumour-suppressive effect.
On the other hand, co-culture of monocytes with highly aggres-
sive breast cancer spheroids (MDA-MB-231) increased expression
of MMP1, and decreased expression of MMP2 and MMP9, resulting
in cancer cells and monocytes showing greater migration through
the 3D matrix [19], suggesting a tumour-favouring effect.ocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
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FIGURE 2
Cancer cells can be cultured as spheroids, giving them a 3D structure. Cancer spheroids can be formed using a hanging drop technique (a), ultra-low attachment
plates (b) or in a 3D matrix, such as AlgiMatrixTM (c) or matrix-coated plates (d). These culture methods can be combined to first generate spheroids (a,b) followed
by culture in a 3D matrix (c,d).
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enced by other stromal cells and to contribute actively to cancer
progression. Cancer-associated fibroblasts and cancer cells con-
tribute to the differentiation of M2 macrophages via secretion of
soluble factors, such as interleukin (IL)-6 and stromal-derived
growth factor-1 (SDF-1) [20]. M2 macrophages were shown to
promote invasion via paracrine signalling (conditioned medium
from primary tumour-associated macrophages isolated from
blood) in breast cancer spheroids (SUM159PT) cultured in Cul-
trex1 basement membrane extract [21] and via direct cell–cell
interactions during co-culture of mouse breast cancer spheroids
with bone-marrow-derived macrophages in collagen type I [22].
Spheroid cultures were also studied using the AlgimatrixTM 3D
culture system, a porous alginate cell culture platform, to assess
macrophage effect on fibroblasts and cancer spheroids (Fig. 2c).
Co-culture of mouse breast cancer cells with mouse fibroblasts had
a negative impact on cancer spheroid formation, whereas a co-
culture with mouse macrophages inhibited their growth capacity
in 3D. Only a triple culture of macrophages, fibroblasts and breast
cancer cells resulted in an increase in the amount of spheroids
formed, indicating the need for interaction between the three cell
populations for cancer growth [23]. By contrast, a study on orga-
notypic co-culture of air-exposed murine squamous cell carcino-
ma cells grown as a layer on top of murine dermal fibroblasts in rat-
tail collagen type I (Fig. 3a) showed that the addition of macro-
phages to the dermal collagen compartment led to polarisation
into the M2 phenotype by fibroblasts and cancer cells. The pres-
ence of M2 macrophages induced squamous cell carcinoma cellPlease cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immuninvasion into type I collagen by disrupting the basement mem-
brane. Increased collagenolytic activity via MMP-2 and MMP-9
was observed. Authors showed similar effects when using human
skin squamous cell carcinoma cells, human primary dermal fibro-
blasts and human monocyte-derived macrophages [24].
Macrophages have been studied as a delivery system for
nanotherapeutics. Glioma spheroids were co-cultured with gold-
nanoshell-containing macrophages in ultra-low attachment
(Fig. 2b) plates for photothermal therapy (PTT) and photodynamic
therapy (PDT) investigations. PTT treatment caused growth inhi-
bition in glioma spheroids with gold nanoshells containing
macrophages, whereas it had no effect in monoculture or co-
culture with unloaded macrophages. PDT treatment showed simi-
lar results but a lower need for radiant exposure, indicating it can
be more efficient than PTT [25]. This model was further confirmed
in vivo, where mice with glioma spheroids were injected with gold
nanoshells containing macrophages and PTT treatment resulted in
eradication of cancer cells [26].
Microfluidic systems are 3D models with high-throughput ca-
pacity and the ability to process multiple assays in an automated
manner. Incorporation of tissue engineering has increased the
complexity of these systems, enabling the design of mimetic
environments according to organ or tissue type [27]. The interac-
tion of melanoma cells (B16.F10) with immune cells was evaluated
using such a model: using wild-type immune cells and interferon
regulatory factor (IRF)-8 knockout immune cells, it was shown that
immune cells require IRF-8 to interact with cancer cells and limit
their invasiveness. This is in concordance with the findings in an inocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
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FIGURE 3
Tissue-engineered approaches use natural and artificial scaffolds to provide cells with a 3D extracellular matrix. Natural scaffolds include collagen type I hydrogel,
where cancer cells are cultured on top of gel populated with stromal cells (a) or within the collagen matrix enabling spheroid formation (b). Artificial scaffolds
include chitosan–alginate where cancer cells are seeded within the scaffold (c). Extracellular matrix can be also added to a microfluidic device containing channels
for cancer and stromal cells (d).
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nosurveillance [28,29]. In another approach, tumour vasculature
was added to the 3D microfluidic cancer model (Fig. 3d). Here, the
tumour channel was populated with human breast carcinoma
(MDA231) cells and the endothelial channel with endothelial cells
(HUVEC). The two channels were interconnected via 3D ECM
hydrogel and cancer cells invaded into the 3D ECM, and endothe-
lial cells formed a layer on the top of the ECM. When macrophages
(murine RAW264.7) were added to the tumour channel, tumour
cells had higher rates of intravasation into the endothelial cell
layer as a result of macrophage-induced permeability. These
macrophages had variable expression of M1- and M2-specific
markers, and secreted tumour necrosis factor (TNF)-a, a proin-
flammatory cytokine released by M1 macrophages, showing that a
heterogeneous macrophage population can also lead to a malig-
nant tumour phenotype [30].
Apart from macrophages, the monocytic lineage can also give
rise to other immune cell types. Dendritic cells are antigen-pre-
senting cells that can be derived from haematopoietic bone mar-
row progenitor cells, or from monocytes. Upon activation,
dendritic cells promote an immune response. 3D models have
also been used to study the interaction between these cells and
cancer cells. Dendritic cells derived from peripheral blood-derived
monocytes were used in glioma (U87 and U251 cell lines) spheroid
models cultured in agar-coated flasks to study migration of den-
dritic cells following aminolevulinic acid (ALA)/PDT treatment.
After treatment, immature dendritic cells were attracted to the
glioma spheroids, whereas control spheroids showed no or weakPlease cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun
6 www.drugdiscoverytoday.comattraction. ALA/PDT treatment also resulted in significant uptake
of tumour material by dendritic cells and their maturation, which
can result in an immune response rather than immunological
tolerance [31]. This correlates with the known role of dendritic
cells in immune response, suggesting biomimicry between the
model and clinical response.
Neutrophils
Like monocytes, neutrophils are phagocytic cells derived from
myeloid progenitors found in tumours; yet their role in cancer
growth has not been studied extensively in vitro. Neutrophils have
been shown to infiltrate cervical cancer spheroids (HeLa cell line)
and lung cancer spheroids (A549 cell line) formed in agarose-coated
wells. The relationship between monocyte and neutrophil infiltra-
tion is complex and inter-related. Studies have shown that, when
spheroids were infiltrated by CD14+ monocytes, there was a subse-
quent decrease in neutrophil infiltration. By contrast, prior neutro-
phil infiltration had no effect on subsequent monocyte infiltration.
Similarly, macrophage-depleted tumours in mice showed higher
infiltration with neutrophils [32]. The infiltration of neutrophils
into lung cancer spheroids was mediated by chemokine (C-X-C
motif) ligand (CXCL) and led to an increase in the spheroid growth
rate indicating that neutrophils secrete factors that affect tumour
cell proliferation, possibly including proangiogenic molecules such
as vascular endothelial growth factor (VEGF). Similarly, in vivo a
chemokine (C-X-C motif) receptor (CXCR) 2/ mouse model
showed decreased neutrophil infiltration into tumours, which
was associated with slower tumour growth [33].ocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
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Lymphocytes originate from common lymphoid progenitors and
can be divided into three major groups of cells: T lymphocytes, B
lymphocytes and natural killer (NK) cells. The role of lymphocytes
in the immune response is widespread, from direct cytotoxicity to
regulation of response of other immune cells. Likewise, other
immune cells also regulate lymphocytic activity.
Like tumour-associated macrophages, myeloid-derived suppres-
sor cells (MDSCs) have the capacity to suppress the adaptive
immune response mediated by CD4+ and CD8+ T cells and the
cytotoxic activities of NK cells. Additionally, MDSCs stimulate
tumour growth by promoting cellular stemness, angiogenesis
and metastatic spread of tumour [34]. Th1 lymphocytes repress
or stimulate the activity of other immune cells and a Th1-enriched
microenvironment can reduce the MDSC population and attenu-
ate their suppressive activity. This has been shown to reduce the
size of breast cancer cell line spheres (SK-BR-3 and MDA-MB-231)
cultured in Matrigel1 [35]. In further studies, the same authors
used a 3D co-culture of pancreatic cancer cells (MiaPaCa-2 and
MiaM) and PBMC-derived CD3+ T cells treated with a chemical
heteroconjugation of anti-CD3 and anti-EGFR antibodies. Here,
treatment led to attenuation of the suppressive powers of the
MDSC population and increase in cancer cell cytotoxicity, espe-
cially in Th1-rich environments [36].
Matrigel1 has been used to develop a 3D co-culture model of
breast cancer cells (MCF-7 and MDA-MB-231) with regulatory T
(TREG) lymphocytes (CD4
+CD25+), cells associated with induction
of tumour tolerance and suppression of antitumour T and NK cell
cytotoxic responses, and NK cells (CD56+/NKp46+). In this study,
NK cells were able to disrupt MCF-7 cell masses regardless of TREG
presence; whereas under TREG presence alone the cell clusters
remained unchanged. NK cells also disrupted MDA-MB-231 cell
networks regardless of TREG presence, and in the co-culture with
just TREG and cancer cells distinct stellate networks were noted
[37].
Using a 3D glioma model, NK cells showed lower toxicity to cells
grown in 3D than on cells grown in monolayer. Here, the U251
glioma cell line cultured in the rotary cell culture system formed
spheroids containing on average 4000 cells after 6 days (dimension
400–500 mm). Of note, the cells grown in 3D were also more likely
to generate a tumour when implanted in nude mice reconstituted
with human NK cells [38]. This suggests that in the 3D model, by
unknown mechanisms, cells were provided with protection
against cytotoxic action.
Using a 3D porous chitosan–alginate (CA) scaffold (Fig. 3c)
prostate cancer spheroids attracted CD45+ cells to their surface
within 2 days, with CD45+ cell infiltration occurring after 6 days of
culture. Some populations of these CD45+ cells also expressed CD8
(a marker present on T cells, NK cells and rarely on monocytes and
neutrophils) and CD57 (present on NK cells), indicating hetero-
geneous lymphocyte population. In this study, the CA scaffold
showed advantages over Matrigel1 in a prolonged culture and
enabled recovering cells for further analysis using flow cytometry
[39]. CA scaffolds were further used to evaluate T cell interactions
with murine mammary carcinoma cells. T cell binding and infil-
tration of cancer spheroids was shown to be facilitated by cancer
cell expression of chemokine (C–C motif) ligand (CCL)21, respon-
sible for directing immune effector cell migration, and interferonPlease cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun(IFN)-g, a molecule that activates effector adaptive immune cells
[40]. Additionally, the presence of fibroblasts in the cancer/T cell
spheroids resulted in increased immune suppression as shown by a
decrease in the expression of TNF-a by T cells [41], indicating the
need for complex stromas when studying cancer–immune-cell
interaction in 3D models.
Using spheroid cultures in low attachment plates enabled the
investigation of subpopulations of cancer stem cells in cervical
cancer and head and neck carcinoma cell lines and their suscepti-
bility to cytotoxic T lymphocyte mediated immune responses.
These cancer spheroids had higher expression of stem cell markers
(ALDH, SOX2, Nanog and Oct3/4) than their monoculture equiva-
lents and were lysed by as few as 100 cytotoxic T lymphocytes.
Lysis appeared to be mediated by MHC class I restricted cytolysis
and was enhanced by IFN-g treatment, and occurred at lower levels
when compared to monolayers [42]. These results indicate that
spheroid cultures provide more-heterogeneous cell populations, as
well as a protective mechanism against cytotoxic action, both of
which affect immune response. This in turn suggests that 3D
models could be more clinically relevant and biomimetic than
cell monolayers.
Finally, the role of cytokine-induced killer cells (CIK), immune
effector cells with T-cell- and NK-cell-like phenotype, has been
studied in models of gastric cancer. The 3D engineered model used
collagen type I (Fig. 3b) as a matrix for BGC823 stomach adeno-
carcinoma cell line, which formed multiple spheroids within the
collagen matrix. When CIK were added to the cell culture medium
of the 3D model, CIK were able to infiltrate the collagen matrix,
migrate towards tumour spheroids and surround them, leading to
tumour cell death [43]. This mimicking of immune cell action
shows the potency of 3D in vitro models.
Concluding remarks
The interaction between the various components of the immune
system, cancer and stromal cells is essential for tumour establish-
ment and progression. 3D models have helped to elucidate some
of these interactions. Some studies have shown a parallel between
results in 3D models and in vivo models, which is reassuring and
encourages further use of these platforms. Nevertheless, substan-
tial development in this area is still needed. Most data were
derived using cell lines, which have been argued to have a very
distinct behaviour when compared with patient-derived cells; the
control is often provided by animal models, a system known to be
flawed in terms of studying immune interactions, and different
3D models have been used, limiting comparisons across results.
Building or engineering immunocompetent 3D cancer systems
that can mimic human immune response is challenging. Never-
theless, these systems can provide increased knowledge on the
role of the immune system in cancer as well as serve as less
expensive, more-reproducible models that can be humanised
compared with animal models and can be used for drug and
therapeutic development.
Acknowledgements
Agata Nyga, Joana Neves and Katerina Stamati are funded by the
NIHR Invention for Innovation (i4i) programme. The views
expressed are those of the authors and not necessarily those of the
NHS, the NIHR or the UK Department of Health.ocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
www.drugdiscoverytoday.com 7
REVIEWS Drug Discovery Today  Volume 00, Number 00 April 2016
DRUDIS-1792; No of Pages 8
R
eview
s
P
O
S
T
S
C
R
E
E
NReferences1 Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation.
Cell 144, 646–674
2 Nyga, A. et al. (2011) 3D tumour models: novel in vitro approaches to cancer studies.
J. Cell Commun. Signal. 5, 239–248
3 Branco da Cunha, C. et al. (2014) Influence of the stiffness of three-dimensional
alginate/collagen-I interpenetrating networks on fibroblast biology. Biomaterials 35,
8927–8936
4 Chaudhuri, O. et al. (2014) Extracellular matrix stiffness and composition jointly
regulate the induction of malignant phenotypes in mammary epithelium. Nat.
Mater. 13, 970–978
5 Seano, G. et al. (2013) Modeling human tumor angiogenesis in a three-dimensional
culture system. Blood 121, e129–e137
6 Kim, H. et al. (2012) Changes in global gene expression associated with 3D structure
of tumors: an ex vivo matrix-free mesothelioma spheroid model. PLoS ONE 7, e39556
7 Teng, M.W. et al. (2015) From mice to humans: developments in cancer
immunoediting. J. Clin. Invest. 125, 3338–3346
8 Sica, A. et al. (2006) Tumour-associated macrophages are a distinct M2 polarised
population promoting tumour progression: potential targets of anti-cancer therapy.
Eur. J. Cancer 42, 717–727
9 Meng, F. et al. (2014) Interaction between pancreatic cancer cells and tumor-
associated macrophages promotes the invasion of pancreatic cancer cells and the
differentiation and migration of macrophages. IUBMB Life 66, 835–846
10 Leek, R.D. et al. (1996) Association of macrophage infiltration with angiogenesis
and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625–4629
11 Xuan, Q.J. et al. (2014) Tumor-associated macrophages are correlated with
tamoxifen resistance in the postmenopausal breast cancer patients. Pathol. Oncol.
Res. 20, 619–624
12 Hauptmann, S. et al. (1993) Macrophages and multicellular tumor spheroids in co-
culture: a three-dimensional model to study tumor-host interactions. Evidence for
macrophage-mediated tumor cell proliferation and migration. Am. J. Pathol. 143,
1406–1415
13 Silzle, T. et al. (2003) Tumor-associated fibroblasts recruit blood monocytes into
tumor tissue. Eur. J. Immunol. 33, 1311–1320
14 Ksiazkiewicz, M. et al. (2010) Importance of CCL2-CCR2A/2B signaling for
monocyte migration into spheroids of breast cancer-derived fibroblasts.
Immunobiology 215, 737–747
15 Hoffmann, T.K. et al. (2009) A novel mechanism for anti-EGFR antibody action
involves chemokine-mediated leukocyte infiltration. Int. J. Cancer 124, 2589–2596
16 Guiet, R. et al. (2011) The process of macrophage migration promotes matrix
metalloproteinase-independent invasion by tumor cells. J. Immunol. 187, 3806–3814
17 Milke, L. et al. (2013) Depletion of tristetraprolin in breast cancer cells increases
interleukin-16 expression and promotes tumor infiltration with monocytes/
macrophages. Carcinogenesis 34, 850–857
18 Blot, E. et al. (2003) Cooperation between monocytes and breast cancer cells
promotes factors involved in cancer aggressiveness. Br. J. Cancer 88, 1207–1212
19 Chimal-Ramirez, G.K. et al. (2013) MMP1, MMP9, and COX2 expressions in
promonocytes are induced by breast cancer cells and correlate with collagen
degradation, transformation-like morphological changes in MCF-10A acini, and
tumor aggressiveness. Biomed. Res. Int. 2013, 279505
20 Comito, G. et al. (2014) Cancer-associated fibroblasts and M2-polarized
macrophages synergize during prostate carcinoma progression. Oncogene 33,
2423–2431
21 Mohamed, M.M. et al. (2014) Cytokines secreted by macrophages isolated from
tumor microenvironment of inflammatory breast cancer patients possess
chemotactic properties. Int. J. Biochem. Cell Biol. 46, 138–147
22 Bengsch, F. et al. (2014) Cell type-dependent pathogenic functions of overexpressed
human cathepsin B in murine breast cancer progression. Oncogene 33, 4474–4484
23 Rama-Esendagli, D. et al. (2014) Spheroid formation and invasion capacity are
differentially influenced by co-cultures of fibroblast and macrophage cells in breast
cancer. Mol. Biol. Rep. 41, 2885–2892
24 Linde, N. et al. (2012) Integrating macrophages into organotypic co-cultures: a 3D in
vitro model to study tumor-associated macrophages. PLoS ONE 7, e40058
25 Baek, S.K. et al. (2011) Photothermal treatment of glioma: an in vitro study of
macrophage-mediated delivery of gold nanoshells. J. Neurooncol. 104, 439–448
26 Madsen, S.J. et al. (2015) Nanoparticle-loaded macrophage-mediated photothermal
therapy: potential for glioma treatment. Lasers Med. Sci. 30, 1357–1365
27 Perestrelo, A.R. et al. (2015) Microfluidic organ/body-on-a-chip devices at the
convergence of biology and microengineering. Sensors 15, 31142–31170Please cite this article in press as: Nyga, A. et al. The next level of 3D tumour models: immun
8 www.drugdiscoverytoday.com28 Mattei, F. et al. (2014) A multidisciplinary study using in vivo tumor models and
microfluidic cell-on-chip approach to explore the cross-talk between cancer and
immune cells. J. Immunotoxicol. 11, 337–346
29 Agliari, E. et al. (2014) Cancer-driven dynamics of immune cells in a microfluidic
environment. Sci. Rep. 4, 6639
30 Zervantonakis, I.K. et al. (2012) Three-dimensional microfluidic model for tumor
cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 109,
13515–13520
31 Etminan, N. et al. (2011) Heat-shock protein 70-dependent dendritic cell activation
by 5-aminolevulinic acid-mediated photodynamic treatment of human
glioblastoma spheroids in vitro. Br. J. Cancer 105, 961–969
32 Pahler, J.C. et al. (2008) Plasticity in tumor-promoting inflammation: impairment
of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia
10, 329–340
33 Tazzyman, S. et al. (2011) Inhibition of neutrophil infiltration into A549 lung
tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with
reduced tumor growth. Int. J. Cancer 129, 847–858
34 Ugel, S. et al. (2015) Tumor-induced myeloid deviation: when myeloid-derived
suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125, 3365–3376
35 Thakur, A. et al. (2012) A Th1 cytokine-enriched microenvironment enhances
tumor killing by activated T cells armed with bispecific antibodies and inhibits the
development of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 61,
497–509
36 Thakur, A. et al. (2013) Microenvironment generated during EGFR targeted killing
of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through
COX2 and PGE2 dependent pathway. J. Transl. Med. 11, 35
37 Augustine, T.N. et al. (2015) Establishment of a heterotypic 3D culture system to
evaluate the interaction of T lymphocytes and NK cells with breast cancer. J.
Immunol. Methods 426, 1–13
38 He, W. et al. (2014) Proteomic comparison of 3D and 2D glioma models reveals
increased HLA-E expression in 3D models is associated with resistance to NK cell-
mediated cytotoxicity. J. Proteome Res. 13, 2272–2281
39 Florczyk, S.J. et al. (2012) 3D porous chitosan-alginate scaffolds: a new matrix for
studying prostate cancer cell-lymphocyte interactions in vitro. Adv. Healthc. Mater. 1,
590–599
40 Phan-Lai, V. et al. (2014) CCL21 and IFNgamma recruit and activate tumor specific T
cells in 3D scaffold model of breast cancer. Anticancer Agents Med. Chem. 14, 204–210
41 Phan-Lai, V. et al. (2013) Three-dimensional scaffolds to evaluate tumor associated
fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules
14, 1330–1337
42 Liao, T. et al. (2013) Susceptibility to cytotoxic T cell lysis of cancer stem cells
derived from cervical and head and neck tumor cell lines. J. Cancer Res. Clin. Oncol.
139, 159–170
43 Sun, P. et al. (2013) An engineered three-dimensional gastric tumor culture model
for evaluating the antitumor activity of immune cells in vitro. Oncol. Lett. 5, 489–494
44 Doseff, A.I. and Parihar, A. (2012) Monocyte subsets and their role in tumor
progression. In Tumor Microenvironment and Myelomonocytic Cells (Biswas, S.K.,
ed.), InTech
45 Hollmen, M. et al. (2015) Characterization of macrophage – cancer cell crosstalk in
estrogen receptor positive and triple-negative breast cancer. Sci. Rep. 5, 9188
46 Hargadon, K.M. (2013) Tumor-altered dendritic cell function: implications for anti-
tumor immunity. Front. Immunol. 4, 192
47 Eruslanov, E.B. et al. (2014) Tumor-associated neutrophils stimulate T cell responses
in early-stage human lung cancer. J. Clin. Invest. 124, 5466–5480
48 Vivier, E. et al. (2012) Targeting natural killer cells and natural killer T cells in cancer.
Nat. Rev. Immunol. 12, 239–252
49 Ahn, S.G. et al. (2015) Current issues and clinical evidence in tumor-infiltrating
lymphocytes in breast cancer. J. Pathol. Transl. Med. 49, 355–363
50 Palucka, A.K. and Coussens, L.M. (2016) The basis of oncoimmunology. Cell 164,
1233–1247
51 Qi, W. et al. (2013) Correlation between Th17 cells and tumor microenvironment.
Cell. Immunol. 285, 18–22
52 Hegmans, J.P. and Aerts, J.G. (2014) Immunomodulation in cancer. Curr. Opin.
Pharmacol. 17, 17–21
53 Silva-Santos, B. et al. (2015) gammadelta T cells in cancer. Nat. Rev. Immunol. 15,
683–691
54 Zhang, Y. et al. (2015) Regulatory B cells in anti-tumor immunity. Int. Immunol. 27,
521–530ocompetence, Drug Discov Today (2016), http://dx.doi.org/10.1016/j.drudis.2016.04.010
